137 related articles for article (PubMed ID: 30642820)
1. BTK/PD-1 blockade for treatment of Richter's transformation.
Tang PS; Tam CS
Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820
[No Abstract] [Full Text] [Related]
2. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C
Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754
[No Abstract] [Full Text] [Related]
3. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
4. In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.
Med Lett Drugs Ther; 2018 Nov; 60(1559):e184. PubMed ID: 30681658
[No Abstract] [Full Text] [Related]
5. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
[No Abstract] [Full Text] [Related]
6. BTK Inhibitors and Chemoimmunotherapy for CLL.
Thompson P
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S22-S24. PubMed ID: 32862855
[No Abstract] [Full Text] [Related]
7. Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
Colado A; Marín Franco JL; Elías EE; Amondarain M; Vergara Rubio M; Sarapura Martínez V; Cordini G; Fuentes F; Balboa L; Fernandez Grecco H; Pavlovsky M; Bezares F; Morande P; Giordano M; Gamberale R; Borge M
Am J Hematol; 2020 Jul; 95(7):E174-E178. PubMed ID: 32267009
[No Abstract] [Full Text] [Related]
8. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
Woyach JA
Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
[No Abstract] [Full Text] [Related]
9. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
Roeker LE; Thompson M; Mato AR
Drugs; 2022 Feb; 82(2):133-143. PubMed ID: 34932207
[TBL] [Abstract][Full Text] [Related]
10. CLL in focus: news in the treatment of chronic lymphocytic leukemia.
Schuyler D
Clin Adv Hematol Oncol; 2020 Oct; 18(10):627-628. PubMed ID: 33201868
[No Abstract] [Full Text] [Related]
11. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
Zent CS; Brady MT; Delage C; Strawderman M; Laniewski N; Contant PN; Kanagaiah P; Sangster MY; Barr PM; Chu CC; Topham DJ; Friedberg JW
Leukemia; 2021 Jun; 35(6):1788-1791. PubMed ID: 33128020
[No Abstract] [Full Text] [Related]
12. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A
J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Bruton Tyrosine Kinase Inhibitors.
Stephens DM; Byrd JC
J Clin Oncol; 2020 Sep; 38(25):2937-2940. PubMed ID: 32673168
[No Abstract] [Full Text] [Related]
14. Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.
Rogers KA; Huang Y; Dotson E; Lundberg J; Andritsos LA; Awan FT; Woyach JA; Byrd JC
Br J Haematol; 2019 Apr; 185(2):363-366. PubMed ID: 30028000
[No Abstract] [Full Text] [Related]
15. Targeted Therapy in Chronic Lymphocytic Leukemia.
Kipps TJ; Choi MY
Cancer J; 2019; 25(6):378-385. PubMed ID: 31764118
[TBL] [Abstract][Full Text] [Related]
16. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Awan FT; Thirman MJ; Patel-Donnelly D; Assouline S; Rao AV; Ye W; Hill B; Sharman JP
Leuk Lymphoma; 2019 Aug; 60(8):1972-1977. PubMed ID: 30633573
[TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
18. Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.
Bossory Goike L; Dean S
Vasc Med; 2020 Jun; 25(3):281-282. PubMed ID: 32146868
[No Abstract] [Full Text] [Related]
19. Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia.
Buske C
Lancet Haematol; 2020 Feb; 7(2):e85-e86. PubMed ID: 31866282
[No Abstract] [Full Text] [Related]
20. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma G; Johnson TP; Advani RH
Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]